-
公开(公告)号：US20210401954A1
公开(公告)日：2021-12-30
申请号：US17384055
申请日：2021-07-23
Applicant: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE , MUSEUM NATIONAL D'HISTOIRE NATURELLE , ECOLE NATIONALE VETERINAIRE D'ALFORT
Inventor： Luis G. BERMUDEZ-HUMARAN , Thibault ALLAIN , Isabelle FLORENT , Philippe LANGELLA , Philippe GRELLIER , Marie-Agnes TRAVERS , Bruno POLACK
IPC: A61K38/50 , A23L33/135 , C12N9/80 , A61K38/00 , A61K38/16 , A61K38/46 , A61K35/741 , A61K35/744 , G01D5/24 , H03K17/955
Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.
-
2.发明申请公开(公告)号：US20130273532A1
公开(公告)日：2013-10-17
申请号：US13730243
申请日：2012-12-28
Applicant: Institut Pasteur , Centre National de la Recherche Scientifique , Institut National de la Recherche Agronomique (INRA) , Ecole Nationale Veterinaire D'Alfort , Institut Curie
Inventor： Jean-Jacques Panthier , Giorgia Egidy , Xavier Sastre-Garau , Florence Bernex
IPC: G01N33/68
CPC classification number: G01N33/6893 , C12Q1/6886 , C12Q2600/112 , C12Q2600/158 , G01N33/5743 , G01N2333/705 , G01N2333/9121
Abstract: The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein.
Abstract translation: 本发明涉及用于诊断哺乳动物黑素瘤的方法，包括检测所述哺乳动物的黑素细胞细胞中RACK-1蛋白的过表达，以及从RACK-1蛋白的过表达中减少黑素瘤的存在。 本发明还涉及一种用于确定哺乳动物黑素细胞细胞的肿瘤状态的方法，其包括检测黑素细胞细胞中RACK-1蛋白的过度表达，以及所述细胞的肿瘤状态从过表达 RACK-1蛋白。
-
公开(公告)号：US20230232882A1
公开(公告)日：2023-07-27
申请号：US17999668
申请日：2021-06-03
Applicant: Institut national de recherche pour I'agriculture, I'alimentation et I'environnement , ECOLE NATIONALE VETERINAIRE D'ALFORT , UNIVERSITE PARIS EST CRETEIL VAL DE MARNE , CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS , Biologicke Centrum AV CR v. v. i.
Inventor： Alejandro CABEZAS-CRUZ , Lourdes MATEOS-HERNANDEZ , Astrid Sibylle HOLZER , Luis BERMUDEZ-HUMARAN , Veronica RISCO-CASTILLO , Jose de Jesus DE LA FUENTE-GARCIA , Edgar TORRES-MARAVILLA , Jacques GUILLOT
IPC: A23L33/135 , A23K50/75 , A23K50/80 , A61K39/108 , A61K9/00
CPC classification number: A23L33/135 , A23K50/75 , A23K50/80 , A61K39/0258 , A61K9/0053 , A61K2039/522
Abstract: The present invention concerns an E. coli strains expressing high level of α-Gal, in particular selected in the group consisting of E. coli Nissle 1917 strain, E. coli O111 strain, E. coli O86:B7 strain, and mixture thereof, as a probiotic and/or feed additive and/or oral vaccine in a non-human animal, in particular fish and poultry, to prevent and/or reduce an infectious disease caused by a pathogen expressing α-Gal on its surface.
-
公开(公告)号：US10144975B2
公开(公告)日：2018-12-04
申请号：US14395105
申请日：2013-04-19
Applicant: Institut Pasteur , Universite Paris Descartes , Assistance Publique-Hopitaux de Paris , Pathoquest , Ecole Nationale Veterinaire D'Alfort
Inventor： Marc Eloit , Justine Cheval , Charles Hebert , Marc Lecuit
Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
-
5.发明申请Anellovirus Genome Quantification as a Biomarker of Immune Suppression 审中-公开Anellovirus基因组定量作为免疫抑制的生物标志物公开(公告)号：US20150132260A1
公开(公告)日：2015-05-14
申请号：US14395105
申请日：2013-04-19
Applicant: INSTITUT PASTEUR , UNIVERSITE PARIS DESCARTES , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS , PATHOQUEST , ECOLE NATIONALE VETERINAIRE D'ALFORT
Inventor： Marc Eloit , Justine Cheval , Charles Hebert , Marc Lecuit
IPC: C12Q1/70
CPC classification number: C12Q1/701 , C12Q2600/106 , C12Q2600/158
Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
Abstract translation: 本发明涉及用于确定免疫抑制的抗病毒载量的测量的用途。 更准确地说，本发明提供了表征受试者的免疫抑制或非免疫抑制状态的方法，包括以下步骤：从所述受试者的生物样品中测定非病毒载体，并从所述比较中确定免疫抑制或非免疫抑制状态， 免疫抑制状态。 然后可以使用受试者的免疫抑制状态的测定来设计或适应治疗性治疗。
-
Patent Agency Ranking
公开(公告)号：US20210077759A1
公开(公告)日：2021-03-18
申请号：US17048263
申请日：2019-04-12
Applicant: UNIVERSITE DE SHERBROOKE , ECOLE NATIONALE VETERINAIRE D'ALFORT , lNSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
Inventor： Philippe MICHEAU , Renaud TISSIER , Matthias KOHLHAUER , Julien MOUSSEAU , Mathieu NADEAU , Jonathan VANDAMME
Abstract: Liquid ventilator and methods integrating the concept of total liquid ventilation (TLV) using liquid volumes below functional residual capacity (FRC) of mammal's lungs are disclosed. Beyond the automatization of the whole process, the technology has been up-scaled to confirm that TLV at residual volumes below FRC can provide a safe procedure while enabling the full potential of TLV in a mammal such as humans or adult-sized animals. Such tidal liquid ventilation strongly differs from the previously known TLV approach, opening promising perspectives for a safer clinical translation. Also disclosed are apparatus and method for safe and fast induction of hypothermia during liquid ventilation of a mammal.
-
公开(公告)号：US20210032705A1
公开(公告)日：2021-02-04
申请号：US17011990
申请日：2020-09-03
Applicant: INSTITUT PASTEUR , ECOLE NATIONALE VETERINAIRE D'ALFORT , PATHOQUEST , L'ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
Inventor： Marc ELOIT , Nicolas TORNO , Jean DEREGNAUCOURT , Marion MOUTON , Isabelle HEARD , Philippe PEROT
IPC: C12Q1/6886 , C12Q1/70 , G16H50/30
Abstract: The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.
-
公开(公告)号：US10808284B2
公开(公告)日：2020-10-20
申请号：US15319893
申请日：2015-07-07
Applicant: INSTITUT PASTEUR , ECOLE NATIONALE VETERINAIRE D'ALFORT , PATHOQUEST , L'ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
Inventor： Marc Eloit , Nicolas Torno , Jean Deregnaucourt , Marion Mouton , Isabelle Heard , Philippe Perot
IPC: C12Q1/6886 , C12Q1/70 , G16H50/30
Abstract: The present invention provides compositions, kits, and method for determining the levels of expression of human polyoma or papillomavirus species and RNA transcripts. These levels can be used for the prognosis of risk of developing virally-induced cancers. The ratio (R) between early and late transcripts is indicative of HPV infections associated with higher risk of developing genital neoplasia and cancer.
-
公开(公告)号：US10328132B2
公开(公告)日：2019-06-25
申请号：US15501587
申请日：2015-08-10
Applicant: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE , MUSEUM NATIONAL D'HISTOIRE NATURELLE , ECOLE NATIONALE VETERINAIRE D'ALFORT
Inventor： Luis G. Bermudez-Humaran , Thibault Allain , Isabelle Florent , Philippe Langella , Philippe Grellier , Marie-Agnes Travers , Bruno Polack
IPC: A61K48/00 , A61K35/747 , A61K38/50 , A61K38/00 , A61K38/16 , A61K38/46 , A61K35/741 , A61K35/744 , A23L33/135 , C12N9/80
Abstract: The present invention relates to a composition exhibiting a bile-salt hydrolase activity for its use for the treatment or the prevention of giardiasis, said composition comprising a bile-salt hydrolase (BSH) enzyme, a bacterium able to secrete a BSH, a recombinant host cell able to secrete a BSH, or a combination thereof. The present invention also relates to the use of a composition exhibiting a BSH activity for the treatment or the prevention of giardiasis, and to a pharmaceutical composition or a food composition comprising, as an active principle, a BSH, a lactic acid bacterium able to secrete a BSH, or a recombinant host cell able to secrete a BSH.
-
公开(公告)号：US12083271B2
公开(公告)日：2024-09-10
申请号：US17048263
申请日：2019-04-12
Applicant: SOCPRA SCIENCES ET GENIE S.E.C. , ECOLE NATIONALE VETERINAIRE D'ALFORT , INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
Inventor： Philippe Micheau , Renaud Tissier , Matthias Kohlhauer , Julien Mousseau , Mathieu Nadeau , Jonathan Vandamme
CPC classification number: A61M16/0054 , A61F7/0085 , A61F7/12 , A61M16/0003 , A61M16/024 , A61M16/1005 , A61M16/1075 , A61F2007/0064 , A61F2007/0086 , A61F2007/126 , A61M2016/0027 , A61M2016/0036 , A61M16/0051 , A61M16/0833 , A61M16/208 , A61M2202/02 , A61M2202/0476 , A61M2205/3368 , A61M2205/3606 , A61M2205/366 , A61M2230/46
Abstract: Liquid ventilator and methods integrating the concept of total liquid ventilation (TLV) using liquid volumes below functional residual capacity (FRC) of mammal's lungs are disclosed. Beyond the automatization of the whole process, the technology has been up-scaled to confirm that TLV at residual volumes below FRC can provide a safe procedure while enabling the full potential of TLV in a mammal such as humans or adult-sized animals. Such tidal liquid ventilation strongly differs from the previously known TLV approach, opening promising perspectives for a safer clinical translation. Also disclosed are apparatus and method for safe and fast induction of hypothermia during liquid ventilation of a mammal.
-
-
-
-
-
-
-
-
-
Search Results
19
records
(took 0.014 seconds)
